Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.38 |
| ▸ | CCR5 | P51681 | 2/20 | 0.38 |
| ▸ | CCR8 | P51685 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 4/20 | 0.37 |
| ▸ | NOS3 | P29474 | 3/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.31 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.31 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25144384 | 0.85 | SMN1; SMN2 (0.37) | CCR1CCR5CCR8NOS2NOS3 | |
| SCHEMBL25700670 | 0.85 | CCR1 (0.34) | CCR1CCR5CCR8NOS2NOS3 | |
| SCHEMBL20457472 | 0.85 | CCR1 (0.34) | CCR1CCR5CCR8NOS2NOS3 | |
| SCHEMBL410301 | 0.79 | CCR1 (0.39) | CCR1CCR5CCR8NOS2NOS3 | |
| SCHEMBL10204659 | 0.79 | NOS2 (0.48) | CCR1CCR5CCR8NOS2NOS3 | |
| SCHEMBL3635124 | 0.77 | CYP3A4 (0.30) | CYP3A4TSHRCYP2C19 | |
| SCHEMBL21718934 | 0.76 | CCR1 (0.37) | CCR1CCR5CCR8NOS2NOS3 | |
| SCHEMBL21709866 | 0.76 | NOS2 (0.56) | CCR1CCR5CCR8NOS2NOS3 | |
| SCHEMBL22096913 | 0.76 | GABRA1 (0.42) | CCR1CCR5CCR8NOS2NOS3 | |
| SCHEMBL21719115 | 0.76 | HPGD (0.41) | CCR1CCR5CCR8NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105801591-B | A kind of five rings pyrroles Alkaloid and preparation method thereof | 中国科学院化学研究所 | 2019-06-18 | — | — | CN | claimed |
| CN-101687120-B | Method for direct elution of reactive18F fluoride ions from anion exchange resins in an organic medium suitable for radiolabelling, without any evaporation step, by using strong organic bases | TRASIS S A | 2013-12-18 | — | — | CN | claimed |
| EP-2164590-A1 | METHOD FOR THE DIRECT ELUTION OF REACTIVE 18F FLUORIDE FROM AN ANION EXCHANGE RESIN IN AN ORGANIC MEDIUM SUITABLE FOR RADIOLABELLING WITHOUT ANY EVAPORATION STEP BY THE USE OF STRONG ORGANIC BASES | Trasis S.A. (BE) | 2010-03-24 | — | — | EP | claimed |
| WO-2009003251-A1 | METHOD FOR THE DIRECT ELUTION OF REACTIVE 18F FLUORIDE FROM AN ANION EXCHANGE RESIN IN AN ORGANIC MEDIUM SUITABLE FOR RADIOLABELLING WITHOUT ANY EVAPORATION STEP BY THE USE OF STRONG ORGANIC BASES | TRASIS S.A. (BE) | 2009-01-08 | — | — | WO | claimed |
| EP-0912477-A1 | PROCESS FOR THE PREPARATION OF 2-ALKENE-1,4-DIOLS AND 3-ALKENE-1,2-DIOLS FROM $g(g),$g(d)-EPOXYALKENES | EASTMAN CHEMICAL COMPANY (US) | 1999-05-06 | — | — | EP | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| WO-1998002404-A1 | PROCESS FOR THE PREPARATION OF 2-ALKENE-1,4-DIOLS AND 3-ALKENE-1,2-DIOLS FROM η,δ-EPOXYALKENES | EASTMAN CHEMICAL COMPANY (US) | 1998-01-22 | — | — | WO | claimed |
| EP-4374929-B1 | METHODS AND DEVICES FOR USING ISOPERILLYL ALCOHOL | UNIV SOUTHERN CALIFORNIA (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024099364-A2 | FUSED MULTICYCLIC COMPOUNDS AND THEIR USE AS PARP1 INHIBITORS | LAEKNA THERAPEUTICS SHANGHAI CO., LTD. (CN) | 2024-05-16 | — | — | WO | disclosed |
| CN-117946114-A | TYK2 inhibitor and application thereof | 武田药品工业株式会社 | 2024-04-30 | — | — | CN | disclosed |
| CN-117946115-A | TYK2 inhibitor and application thereof | 武田药品工业株式会社 | 2024-04-30 | — | — | CN | disclosed |
| US-20240051979-A1 | TREPROSTINIL PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2024-02-15 | — | — | US | disclosed |
| WO-2023193789-A1 | WEE1 DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2023-10-12 | — | — | WO | disclosed |
| US-5144043-A | Coupling protein or peptide to radionucleotide; labeling antibodies | CENTOCOR (US) | 1992-09-01 | — | — | US | disclosed |
| WO-1992012709-A1 | ARYL MACROCYCLIC COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| WO-1992012708-A1 | ANTI-COAGULANT PROPERTIES OF MACROCYCLIC COMPOUNDS AND METHOD OF TREATMENT | GENELABS TECHNOLOGIES, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| US-5045554-A | Fluoro compounds, rice sheath blight, Basidiomycetes type fungus | MONSANTO COMPANY (US) | 1991-09-03 | — | — | US | disclosed |
| US-5026882-A | Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase | SMITHKLINE BEECHAM CORPORATION (US) | 1991-06-25 | — | — | US | disclosed |
| US-5017568-A | Enzyme inhibitors, carboxylation | SMITHKLINE BEECHAM CORPORATION (US) | 1991-05-21 | — | — | US | disclosed |
| EP-0371950-A2 | Substituted thiazoles and their use as fungicides | Monsanto Company (US) | 1990-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051979-A1 | TREPROSTINIL PRODRUGS | TYMP, TK1, DCTPP1 | CCR1 2474/4885CCR5 2332/4885CCR8 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.